PT1015459E - Analogos de rapamicina contendo tetrazole com tempos de meia-vida mais curtos - Google Patents

Analogos de rapamicina contendo tetrazole com tempos de meia-vida mais curtos

Info

Publication number
PT1015459E
PT1015459E PT98949512T PT98949512T PT1015459E PT 1015459 E PT1015459 E PT 1015459E PT 98949512 T PT98949512 T PT 98949512T PT 98949512 T PT98949512 T PT 98949512T PT 1015459 E PT1015459 E PT 1015459E
Authority
PT
Portugal
Prior art keywords
rapamicine
analogs containing
life times
longer short
containing tetrazole
Prior art date
Application number
PT98949512T
Other languages
English (en)
Inventor
Karl W Mollison
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25470968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1015459(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PT1015459E publication Critical patent/PT1015459E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT98949512T 1997-09-26 1998-09-24 Analogos de rapamicina contendo tetrazole com tempos de meia-vida mais curtos PT1015459E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93814497A 1997-09-26 1997-09-26

Publications (1)

Publication Number Publication Date
PT1015459E true PT1015459E (pt) 2005-09-30

Family

ID=25470968

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98949512T PT1015459E (pt) 1997-09-26 1998-09-24 Analogos de rapamicina contendo tetrazole com tempos de meia-vida mais curtos

Country Status (27)

Country Link
EP (1) EP1015459B9 (pt)
JP (1) JP3790424B2 (pt)
KR (3) KR100833812B1 (pt)
CN (1) CN1161360C (pt)
AR (1) AR015940A1 (pt)
AT (1) ATE297398T1 (pt)
AU (1) AU745576B2 (pt)
BG (1) BG64955B1 (pt)
BR (1) BR9812305A (pt)
CA (1) CA2303934C (pt)
CO (1) CO5070656A1 (pt)
CZ (1) CZ299365B6 (pt)
DE (1) DE69830502T2 (pt)
DK (1) DK1015459T3 (pt)
ES (1) ES2244087T3 (pt)
HU (1) HU228368B1 (pt)
IL (2) IL134607A0 (pt)
NO (1) NO325813B1 (pt)
NZ (2) NZ514778A (pt)
PL (1) PL191212B1 (pt)
PT (1) PT1015459E (pt)
SI (1) SI1015459T1 (pt)
SK (1) SK285408B6 (pt)
TR (1) TR200000778T2 (pt)
TW (1) TW557297B (pt)
WO (1) WO1999015530A1 (pt)
ZA (1) ZA988750B (pt)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050163781A1 (en) * 2002-01-29 2005-07-28 Philippe Koninckx Tissue adhesion formation control
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
CA2483594C (en) 2002-05-16 2011-02-15 Novartis Ag Use of edg receptor binding agents in cancer
CA2486853A1 (en) 2002-05-27 2003-12-04 Novartis Ag Bis-aromatic alkanols
NZ538568A (en) * 2002-09-06 2010-09-30 Abbott Lab Medical device having hydration inhibitor
PL408347A1 (pl) 2002-09-24 2014-08-18 Novartis Ag Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P
MXPA05012461A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresores.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
BRPI0518079A (pt) 2004-10-28 2008-11-04 Wyeth Corp usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
PL1909973T3 (pl) 2005-07-15 2019-01-31 Micell Technologies, Inc. Polimerowe powłoki zawierające proszek leku o kontrolowanej morfologii
SG155912A1 (en) 2005-07-25 2009-10-29 Trubion Pharmaceuticals Inc B-cell reduction using cd37-specific and cd20-specific binding molecules
BRPI0617057A2 (pt) 2005-08-30 2011-07-12 Univ Miami anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão
US20070104721A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
EP2944382A1 (en) 2006-04-26 2015-11-18 Micell Technologies, Inc. Coatings containing multiple drugs
NZ574654A (en) * 2006-07-25 2012-03-30 Abbott Lab Crystalline forms of rapamycin analogs
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
MX350637B (es) 2008-04-17 2017-09-11 Micell Technologies Inc Stents que tienen capas bioabsorbibles.
CA2728514C (en) 2008-06-20 2020-08-11 Novartis Ag Paediatric compositions for treating multiple sclerosis
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
CN103204794A (zh) 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
RS53041B (sr) 2008-12-18 2014-04-30 Novartis Ag Hemifumaratna so 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
ES2531831T3 (es) 2008-12-18 2015-03-20 Novartis Ag Forma polimórfica del ácido 1-(4-{1-[(E)-4-ciclohexil-3-trifluorometil-benciloxiimino]-etil}-2-etil-bencil)-azetidin-3-carboxilico
EP2413847A4 (en) 2009-04-01 2013-11-27 Micell Technologies Inc COATED STENTS
CA2759015C (en) 2009-04-17 2017-06-20 James B. Mcclain Stents having controlled elution
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
EP2462165B1 (en) 2009-08-03 2016-05-11 University of Miami Method for in vivo expansion of t regulatory cells
JP2013509444A (ja) 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
MX2012008874A (es) 2010-02-11 2012-08-31 Bristol Myers Squibb Co Macrociclos como inhibidores del factor de coagulacion (fxia).
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CN102844049B (zh) 2010-04-27 2016-06-01 罗切格利卡特公司 无岩藻糖基化CD20抗体与mTOR抑制剂的联合疗法
CN102234288B (zh) * 2010-05-06 2014-07-02 上海医药工业研究院 唑他莫司的制备方法
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
WO2012112847A1 (en) 2011-02-18 2012-08-23 Novartis Pharma Ag mTOR/JAK INHIBITOR COMBINATION THERAPY
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
EA023649B1 (ru) 2011-10-14 2016-06-30 Бристол-Майерс Сквибб Кампани ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОИЗОХИНОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
NZ707990A (en) 2012-10-12 2018-07-27 Bristol Myers Squibb Co Crystalline forms of a factor xia inhibitor
EP2809675A4 (en) * 2012-11-30 2015-08-12 Hangzhou Zylox Pharma Co Ltd ANALOGUE OF RAPAMYCIN AND METHODS OF MANUFACTURING THE SAME
CA2897826C (en) 2013-01-09 2022-09-27 Taylor H. Schreiber Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
CN105307597A (zh) 2013-03-12 2016-02-03 脉胜医疗技术公司 可生物吸收的生物医学植入物
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
EP2996629B1 (en) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
EA201690987A1 (ru) 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
WO2015108912A1 (en) 2014-01-16 2015-07-23 MUSC Foundation for Research and Development Targeted nanocarriers for the administration of immunosuppressive agents
NO2760821T3 (pt) 2014-01-31 2018-03-10
PE20210470A1 (es) 2014-01-31 2021-03-08 Bristol Myers Squibb Co Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
EP3122376A4 (en) 2014-03-27 2017-12-20 The Brigham and Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
PL3129470T3 (pl) 2014-04-07 2021-11-29 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
JP2017518307A (ja) 2014-06-02 2017-07-06 チルドレンズ メディカル センター コーポレーション 免疫調節のための方法および組成物
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
CN107109419B (zh) 2014-07-21 2020-12-22 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
LT3183268T (lt) 2014-08-19 2020-06-10 Novartis Ag Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6815992B2 (ja) 2014-10-08 2021-01-20 ノバルティス アーゲー キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
AU2016263176A1 (en) 2015-05-20 2017-12-07 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
EP3373927A1 (en) 2015-11-11 2018-09-19 Novartis AG Uses of myostatin antagonists, combinations containing them and uses thereof
KR102565885B1 (ko) 2016-07-20 2023-08-09 유니버시티 오브 유타 리서치 파운데이션 Cd229 car t 세포 및 이의 사용 방법
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
KR20190089005A (ko) 2016-11-23 2019-07-29 노파르티스 아게 에베롤리무스, 닥톨리십 또는 둘 다를 사용하여 면역 반응을 증진시키는 방법
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
AU2019310040A1 (en) 2018-07-23 2021-02-11 Enclear Therapies, Inc. Methods of treating neurological disorders
CA3107349A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
KR20230107804A (ko) 2020-09-29 2023-07-18 엔클리어 테라피스, 인크. 지주막하액 관리 방법 및 시스템
US20240016787A1 (en) 2020-11-03 2024-01-18 Rdiscovery, LLC Methods for treatment of cancer and phagocytosis-deficiency related diseases
EP4370160A1 (en) 2021-07-15 2024-05-22 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
CN116082362B (zh) * 2023-01-04 2024-05-10 山东大学 一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
WO1998009972A1 (en) * 1996-09-09 1998-03-12 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries
EP0927182A2 (en) * 1996-09-09 1999-07-07 American Home Products Corporation Alkylated rapamycin derivatives

Also Published As

Publication number Publication date
KR100803639B1 (ko) 2008-02-19
WO1999015530A1 (en) 1999-04-01
NO20001438D0 (no) 2000-03-20
KR20070086925A (ko) 2007-08-27
KR100700319B1 (ko) 2007-03-29
SK4172000A3 (en) 2000-08-14
EP1015459B1 (en) 2005-06-08
IL134607A0 (en) 2001-04-30
JP3790424B2 (ja) 2006-06-28
NO20001438L (no) 2000-05-26
ZA988750B (en) 1999-04-01
ES2244087T3 (es) 2005-12-01
ATE297398T1 (de) 2005-06-15
CN1161360C (zh) 2004-08-11
AR015940A1 (es) 2001-05-30
BG104316A (en) 2000-12-29
DE69830502D1 (de) 2005-07-14
CN1271361A (zh) 2000-10-25
JP2001517671A (ja) 2001-10-09
NZ502896A (en) 2001-12-21
AU9581998A (en) 1999-04-12
HUP0004556A2 (hu) 2001-10-28
KR20010024298A (ko) 2001-03-26
CO5070656A1 (es) 2001-08-28
IL134607A (en) 2006-04-10
EP1015459A1 (en) 2000-07-05
BR9812305A (pt) 2000-09-05
HU228368B1 (en) 2013-03-28
SK285408B6 (sk) 2007-01-04
AU745576B2 (en) 2002-03-21
HUP0004556A3 (en) 2001-12-28
PL339455A1 (en) 2000-12-18
DE69830502T2 (de) 2006-05-11
CA2303934A1 (en) 1999-04-01
KR20060071092A (ko) 2006-06-26
CA2303934C (en) 2010-01-26
CZ20001014A3 (cs) 2000-07-12
NZ514778A (en) 2005-01-28
HK1030771A1 (en) 2001-05-18
KR100833812B1 (ko) 2008-05-30
BG64955B1 (bg) 2006-10-31
PL191212B1 (pl) 2006-03-31
CZ299365B6 (cs) 2008-07-02
SI1015459T1 (en) 2005-10-31
EP1015459B9 (en) 2005-10-12
TR200000778T2 (tr) 2000-07-21
TW557297B (en) 2003-10-11
NO325813B1 (no) 2008-07-21
DK1015459T3 (da) 2005-10-10

Similar Documents

Publication Publication Date Title
PT1015459E (pt) Analogos de rapamicina contendo tetrazole com tempos de meia-vida mais curtos
FI960519A0 (fi) Uusia yhdisteitä
FI973772A0 (fi) Riktad allmaen saendning i ett radionaet
DE69836667D1 (de) Audio-Video-synchronisiertes Wiedergabegerät
DE69900751D1 (de) Kreisel
DE69829353D1 (de) Anzeigegerät
ID25548A (id) Senyawa-senyawa heterosiklik spiroazabisiklik terbaru
FI980616A0 (fi) Foerfarande foer att foerbaettra kvaliteten av en radiofoerbindelse i ett cellulaert radionaet
ID20371A (id) Sistem lampu el dalam bentuk kit
EE03832B1 (et) Heptapeptiidanaloogid
PT971702E (pt) Microgranulos contendo cis-platina
DE69830260D1 (de) Vibrationskreisel
DE69832734D1 (de) Fahrrad- Schalt-Einheit
EP0996458A4 (en) SANDRAMYCIN ANALOG
DE69833078D1 (de) Vibrationskreisel
DE69520277D1 (de) Beschleunigungsmessaufnehmer fürmehrere richtungen
EP0953464A4 (en) LOUVRE
DE69832843D1 (de) Vibrationskreisel
FI972070A0 (fi) Foerfarande foer att bedoema kapacitetsbehovet i olika delar av ett cellulaert radiosystem
DE69837512D1 (de) Vibrationskreisel
FI973486A0 (fi) Datakommunikationsfoerfarande i ett basstationssystem i ett cellulaert radionaet
DE59804724D1 (de) Fadenbremse
DE59812995D1 (de) Abspielgerät
ATE213179T1 (de) Adsorbentzusammenstellung
SE9701339D0 (sv) Specific adsorbents